Comparative Pharmacology
Head-to-head clinical analysis: NORFLEX versus ZANAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORFLEX versus ZANAFLEX.
NORFLEX vs ZANAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from CNS, leading to decreased muscle tone and spasticity.
Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.
Initial: 2 mg orally every 6-8 hours as needed, up to 3 times daily. Maximum: 36 mg per day.
None Documented
None Documented
Terminal elimination half-life: 15-20 hours. Clinical context: Allows twice-daily dosing; steady-state reached in 3-5 days.
Terminal elimination half-life is approximately 2.5 hours in healthy adults; clinically, this short half-life necessitates multiple daily dosing for sustained effect and contributes to its use as needed for spasticity.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; <10% unchanged in feces.
Approximately 95% of a dose is eliminated via hepatic metabolism; renal excretion accounts for about 20% as unchanged drug and metabolites, with about 20% eliminated in feces.
Category C
Category C
Muscle Relaxant
Muscle Relaxant